Comment from IQVIA

Summary: IQVIA, a global provider of advanced analytics and clinical research services, supports the FDA's draft guidance on using AI for regulatory decision-making. They recommend enhancing the guidance by emphasizing real-world testing, incorporating life-cycle monitoring into the core framework, and including specific considerations for generative AI models.